IDO pathway

This forum is to discuss general things concerning TSOI.
Post Reply
trader32176
Posts: 3903
Joined: Fri Jun 26, 2020 5:22 am
Location: the trenches

IDO pathway

Post by trader32176 »

IDO Pathway

December 28, 2021

viewtopic.php?t=538


OCEANSIDE, Calif.--(BUSINESS WIRE)--Therapeutic Solutions International announced today receipt of a Notice of Allowance from the United States Patent and Trademark Office regarding its patent application entitled “Nutraceuticals for Suppressing Indolamine 2,3 Deoxygenase.”

To the knowledge of the Company, this is the first issuance of a patent on a nutraceutical supplement for stimulating the immune system by blocking immune suppressive activities used by cancer and viruses in the IDO pathway. The supplement, termed “QuadraMune®” is commercially available on the Company website and through Amazon.

Numerous drugs such as Optivo®, Yervoy®, and Keytruda®, have been approved by the FDA for treatment of cancers by boosting immunity though blocking immune inhibiting mechanisms. This class of drugs, called “checkpoint inhibitors” represent a 15.2 billion dollar a year market1.

“The indolamine 2,3 deoxygenase (IDO) pathway is believed to be one of the major immunological checkpoints based on the fact that small molecule blockade of this pathway results in immune mediated destruction of tumors in animals,” stated Dr. Thomas Ichim, Board Member and Co-Inventor of the patent. “Unfortunately, prior approaches to suppress this pathway relied on toxic compounds which did not perform well in clinical trials, in part due to inability to administer sufficient doses without evoking toxicity. We are excited by the possibility that QuadraMune®, a nutraceutical composition that is commercially available may act as a potent immune booster targeting the IDO pathway without drawbacks of other approaches.”

In 20132 and subsequently in 20183, Dr. Ichim and colleagues published regression of breast cancer by inhibiting the IDO pathway using an RNA interference approach. The current data and patent granted are representation of years of basic scientific investigation on the relationship between IDO and the immune system.

“As a physician that sees firsthand the devastation caused by cancer and viruses, I am extremely excited about our ability to modulate critical immunological pathways using naturally occurring ingredients such as pterostilbene, thymoquinone, epigallocatechin gallate and sulforaphane,” said Dr. James Veltmeyer, Chief Medical Officer of the Company and Co-Inventor of the patent. “What is particularly important is that after filing of our patents, numerous independent universities have validated the anti-COVID activity of the individual ingredients. These studies are summarized in our previous press release4.”

“The acceptance of our data by the United States Patent Office in granting of the current patent is a major accomplishment for the Company,” said Timothy Dixon, President and CEO, and Co-Inventor of the patent. “The Company has numerous patent applications filed covering multiple nutraceuticals and uses including; a) published patent application #16/866430 entitled ‘Nutraceuticals for the Prevention, Inhibition, and Treatment of SARS-Cov-2 and Associated COVID-19’, b) #16/898472 entitled ‘Nutraceuticals for Reducing Myeloid Suppressor Cells’ and c) #16/907335 entitled ‘Treatment of SARS-CoV-2 with Dendritic Cells for Innate and/or Adaptive Immunity’.”
trader32176
Posts: 3903
Joined: Fri Jun 26, 2020 5:22 am
Location: the trenches

Re: IDO pathway

Post by trader32176 »

and what is the IDO pathway long TSOI ?
User avatar
TimGDixon
Posts: 3317
Joined: Fri Jun 26, 2020 4:36 am
Location: The Bunker
Contact:

Re: IDO pathway

Post by TimGDixon »

Well, this is one of those QM patents that can stand on its own and go to clinical trials. But what is the end game of the trials; to have it FDA approved as a drug. That is a potential of course but the question always remains what does it do to the nutraceutical if the same composition becomes a drug? I wrote a little about this recently here and the dilemma of doing that. However I also pointed out that you can still do clinical trials to carve out claims like we have with NanoStilbene that only we can make.

• Claim #1 - NanoStilbene administration results in superior pharmacokinetic profile compared to powder pterostilbene showing a 55% increase in serum levels over the traditional powder form of pterostilbene.
• Claim #2 - NanoStilbene administration also shows the half-life to be double to that of the powder form.
• Claim #3 – In a clinical study of advanced solid tumor cancer patients NanoStilbene was shown to reduce TNF-a by an overall average of 26%.
• Claim #4 - In a clinical study of advanced solid tumor cancer patients NanoStilbene was shown to reduce IL-6 by an overall average of 26%.
• Claim #5 - In a clinical study of advanced solid tumor cancer patients NanoStilbene was shown to reduce CRP by an overall average of 32%.
• Claim #6 - In a clinical study of advanced solid tumor cancer patients NanoStilbene was shown to increase IFN-g production by an overall average of 12%.
• Claim #7 - In a clinical study of advanced solid tumor cancer patients NanoStilbene was shown to increase NK cell activity by an overall average of 37%.
trustspecialist
Posts: 49
Joined: Sat Aug 28, 2021 3:18 pm

Re: IDO pathway

Post by trustspecialist »

Sooo sorry to beg the question but...do we have a stand alone indication that will be heading to clinical??
Excuse me as I get excited that the company may be exiting the noodling stage and soon be starting FDA Approvals....
curncman
Posts: 1473
Joined: Fri Jun 26, 2020 8:27 am

Re: IDO pathway

Post by curncman »

WOW I interpret that if TSOI conducts clinical trials on QM and if FDA approved we could end with minimum of 7 blockbuster DRUGS for different clinical applications Hence I blindly believe that PPS to over $10 is possible! :lol: :lol: :lol: :lol: :lol: :lol: :lol: :lol: :lol: :lol:
User avatar
TimGDixon
Posts: 3317
Joined: Fri Jun 26, 2020 4:36 am
Location: The Bunker
Contact:

Re: IDO pathway

Post by TimGDixon »

For sure at some stage we will doing cancer trial on IDO inhibition - I can't say when - its on the sketch pad though.
trustspecialist wrote: Wed Jan 12, 2022 4:38 pm Sooo sorry to beg the question but...do we have a stand alone indication that will be heading to clinical??
Excuse me as I get excited that the company may be exiting the noodling stage and soon be starting FDA Approvals....
curncman
Posts: 1473
Joined: Fri Jun 26, 2020 8:27 am

Re: IDO pathway

Post by curncman »

Tim,
The stage is all set for TSOI to take over the WORLD with world class science based Neutraceuticals to heal the post pandemic patients and set new standards in modern medicine!
User avatar
TimGDixon
Posts: 3317
Joined: Fri Jun 26, 2020 4:36 am
Location: The Bunker
Contact:

Re: IDO pathway

Post by TimGDixon »

Thats the plan - to take over the world!
Post Reply